Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK-0616-017 | Other Identifier | MSD | |
| 2022-502782-14-00 | Registry Identifier | EU CT | |
| U1111-1285-4257 | Registry Identifier | UTN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with heterozygous familial hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Enlicitide Decanoate | Experimental | Participants received 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks. |
|
| Placebo | Placebo Comparator | Participants received enlicitide decanoate-matching placebo orally QD for up to 52 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enlicitide Decanoate | Drug | Oral tablet |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 | Blood samples were collected at baseline and at Week 24 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate. | Baseline and Week 24 |
| Number of Participants With Adverse Events (AEs) | An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to 64 weeks (8 weeks postdose) |
| Number of Participants Who Discontinued Study Drug Due to an AE | An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to 56 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Percent Change From Baseline in LDL-C at Week 52 | Blood samples were collected at baseline and at Week 52 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate. | Baseline and Week 52 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alliance for Multispecialty Research, LLC ( Site 0023) | Daphne | Alabama | 36526 | United States | ||
| Excel Medical Clinical Trials ( Site 0008) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41206969 | Result | Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026 Jan 13;335(2):129-139. doi: 10.1001/jama.2025.20620. |
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Enlicitide Decanoate | Participants received 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks. |
| FG001 | Placebo | Participants received enlicitide decanoate-matching placebo orally QD for up to 52 weeks. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 21, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Oral tablet (placebo). |
|
| Mean Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24 |
Blood samples were collected at baseline and at Week 24 to determine mean percent change in non-HDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline non-HDL-C as a covariate. |
| Baseline and Week 24 |
| Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24 | Blood samples were collected at baseline and at Week 24 to determine mean percent change in ApoB. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline ApoB as a covariate. | Baseline and Week 24 |
| Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24 | Blood samples were collected at baseline and at Week 24 to determine percent change in Lp(a). For percent change in Lp(a) at Week 24, the two treatment groups were analyzed using the Wilcoxon signed rank test with Hodges-Lehmann estimation. | Baseline and Week 24 |
| Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24 | Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C <70 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage. | Baseline and Week 24 |
| Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24 | Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C <55 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage. | Baseline and Week 24 |
| Boca Raton |
| Florida |
| 33434 |
| United States |
| Advanced Pharma Research ( Site 0007) | Cutler Bay | Florida | 33189 | United States |
| Progressive Medical Research ( Site 0021) | Port Orange | Florida | 32127 | United States |
| Clinical Site Partners LLC, dba CSP Orlando ( Site 0028) | Winter Park | Florida | 32789 | United States |
| Synexus Clinical Research US - Evansville ( Site 0031) | Evansville | Indiana | 47714 | United States |
| Franciscan Physician Network - Indiana Heart Physicians ( Site 0040) | Indianapolis | Indiana | 46237 | United States |
| Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0001) | Troy | Michigan | 48098 | United States |
| Velocity Clinical Research at The Pioneer Heart Institute, Lincoln ( Site 0026) | Lincoln | Nebraska | 68506 | United States |
| Jubilee Clinical Research ( Site 0030) | Las Vegas | Nevada | 89106 | United States |
| Wake Forest Baptist Health-Cardiovascular Medicine ( Site 0041) | Winston-Salem | North Carolina | 27157 | United States |
| Velocity Clinical Research, Salt Lake City ( Site 0004) | West Jordan | Utah | 84088 | United States |
| Health Research of Hampton Roads, Inc. ( Site 0020) | Newport News | Virginia | 23606 | United States |
| Royal Prince Alfred Hospital-6West CV Ambulatory Care ( Site 2808) | Camperdown | New South Wales | 2050 | Australia |
| Victorian Heart Hospital-Monash Cardiovascular Research Centre (MCRC) ( Site 2803) | Clayton | Victoria | 3168 | Australia |
| Universidade Federal Do Ceara ( Site 0702) | Fortaleza | Ceará | 60430-270 | Brazil |
| Instituto Dante Pazzanese de Cardiology-Fundação Adib Jatene ( Site 0701) | São Paulo | São Paulo | 04012-909 | Brazil |
| Incor - Instituto do Coracao ( Site 0703) | São Paulo | 05403-000 | Brazil |
| Ecogene-21 ( Site 0510) | Chicoutimi | Quebec | G7H 7K9 | Canada |
| Institut de Cardiologie de Montreal ( Site 0506) | Montreal | Quebec | H1T 1C8 | Canada |
| Diex Recherche Trois-Rivieres ( Site 0513) | Trois-Rivières | Quebec | G9A 4P3 | Canada |
| Clinical Research Chile SpA ( Site 0804) | Valdivia | Los Ríos Region | 5110683 | Chile |
| CDIEM ( Site 0814) | Providencia | Region M. de Santiago | 7500859 | Chile |
| Enroll SpA ( Site 0803) | Santiago | Region M. de Santiago | 7500587 | Chile |
| Pontificia Universidad Catolica de Chile-CICUC ( Site 0812) | Santiago | Region M. de Santiago | 8330034 | Chile |
| Fundación Centro de Investigación Clínica CIC ( Site 0906) | Medellín | Antioquia | 050021 | Colombia |
| Ciensalud Ips S A S ( Site 0903) | Barranquilla | Atlántico | 08001 | Colombia |
| Clinica de la Costa S.A.S. ( Site 0902) | Barranquilla | Atlántico | 080020 | Colombia |
| Salud SURA Calle 100 ( Site 0918) | Bogotá | Cundinamarca | 110231 | Colombia |
| Fakultní nemocnice Brno Bohunice-Interni kardiologicka klinika ( Site 3602) | Brno | Brno-mesto | 625 00 | Czechia |
| Institut Klinicke a Experimentalni Mediciny ( Site 3601) | Prague | Praha 4 | 140 21 | Czechia |
| Fakultni Nemocnice u sv. Anny v Brne ( Site 3604) | Brno | South Moravian | 60200 | Czechia |
| Meilahden tornisairaala - Meilahti Tower Hospital ( Site 1300) | Helsinki | Uusimaa | 00290 | Finland |
| Queen Mary Hospital-Medical ( Site 3300) | Pok Fu Lam | Hong Kong |
| Prince of Wales Hospital ( Site 3304) | Shatin | NT | Hong Kong |
| Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Belgyógyászati Klinika ( Site 1603) | Szeged | Csongrád megye | 6725 | Hungary |
| Semmelweis Egyetem-Városmajori Szív- és Érgyógyászati Klinika ( Site 1600) | Budapest | 1122 | Hungary |
| Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Anyagcsere Tanszék) ( Site 1601) | Debrecen | 4032 | Hungary |
| Shaare Zedek Medical Center ( Site 1710) | Jerusalem | 9103102 | Israel |
| Hadassah Medical Center ( Site 1709) | Jerusalem | 9112001 | Israel |
| Rabin Medical Center ( Site 1717) | Petah Tikva | 4941492 | Israel |
| Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 1700) | Sakhnin | 308100 | Israel |
| Radboudumc-internal medicine ( Site 1952) | Nijmegen | Gelderland | 6525 GA | Netherlands |
| Amsterdam UMC, locatie AMC-Vascular Medicine Clin Trial Unit ( Site 1954) | Amsterdam | North Holland | 1105 AZ | Netherlands |
| Vasculair Onderzoek Centrum Hoorn ( Site 1953) | Hoorn | North Holland | 1625 HV | Netherlands |
| Universitair Medisch Centrum Utrecht-Vascular Medicine Research ( Site 1955) | Utrecht | 3584 CX | Netherlands |
| Pacific Clinical Research Network - Rotorua ( Site 2902) | Rotorua | Bay of Plenty | 3010 | New Zealand |
| New Zealand Clinical Research (Christchurch) ( Site 2901) | Christchurch | Canterbury | 8011 | New Zealand |
| Nordlandssykehuset ( Site 2001) | Bodø | Nordland | 8005 | Norway |
| Oslo Universitetssykehus Aker-Lipidklinikken ( Site 2000) | Oslo | 0316 | Norway |
| National University Hospital-Department of Medicine ( Site 3212) | Singapore | Central Singapore | 119074 | Singapore |
| Changi General Hospital ( Site 3211) | Singapore | Central Singapore | 529889 | Singapore |
| Hospital de Sant Joan Despí Moisès Broggi ( Site 2335) | Sant Joan Despí | Catalonia | 08970 | Spain |
| SALUT SANT JOAN DE REUS-BAIX CAMP (EDP)-Vascular and Metabolism Unit ( Site 2329) | Reus | Tarragona | 43204 | Spain |
| HOSPITAL CLINICO DE VALENCIA ( Site 2321) | Valencia | Valenciana, Comunitat | 46010 | Spain |
| Mackay Memorial Hospital -Tamshui Branch ( Site 3109) | New Taipei City | New Taipei | 251 | Taiwan |
| Shin Kong Wu Ho-Su Memorial Hospital ( Site 3106) | Taipei City | Taipei | 111 | Taiwan |
| National Cheng Kung University Hospital-Internal Medicine ( Site 3107) | Tainan | 704 | Taiwan |
| National Taiwan University Hospital ( Site 3100) | Taipei | 10002 | Taiwan |
| Plain Language Summary | View source |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Enlicitide Decanoate | Participants received 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks. |
| BG001 | Placebo | Participants received enlicitide decanoate-matching placebo orally QD for up to 52 weeks. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Baseline Low-density Lipoprotein Cholesterol (LDL-C) | LDL-C was measured at baseline. | Mean | Standard Deviation | mg/dL |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 | Blood samples were collected at baseline and at Week 24 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate. | All participants who have received at least 1 dose of double-blind study intervention and have data for both timepoints. | Posted | Mean | Standard Deviation | Percent Change | Baseline and Week 24 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With Adverse Events (AEs) | An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | All participants who received at least 1 dose of study treatment. One participant received enlicitide decanoate at 56 weeks outside of protocol-specified duration of treatment and was followed for AEs up to 64 weeks (per protocol, 8 weeks postdose). | Posted | Number | Participants | Up to 64 weeks (8 weeks postdose) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants Who Discontinued Study Drug Due to an AE | An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | All participants who received at least 1 dose of study treatment. One participant received enlicitide decanoate at 56 weeks outside of protocol-specified duration of treatment. | Posted | Number | Participants | Up to 56 weeks |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Percent Change From Baseline in LDL-C at Week 52 | Blood samples were collected at baseline and at Week 52 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate. | All participants who have received at least 1 dose of double-blind study intervention and have data for both timepoints. | Posted | Mean | Standard Deviation | Percent Change | Baseline and Week 52 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24 | Blood samples were collected at baseline and at Week 24 to determine mean percent change in non-HDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline non-HDL-C as a covariate. | All participants who have received at least 1 dose of double-blind study intervention and have data for both timepoints. | Posted | Mean | Standard Deviation | Percent Change | Baseline and Week 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24 | Blood samples were collected at baseline and at Week 24 to determine mean percent change in ApoB. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline ApoB as a covariate. | All participants who have received at least 1 dose of double-blind study intervention and have data for both timepoints. | Posted | Mean | Standard Deviation | Percent Change | Baseline and Week 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24 | Blood samples were collected at baseline and at Week 24 to determine percent change in Lp(a). For percent change in Lp(a) at Week 24, the two treatment groups were analyzed using the Wilcoxon signed rank test with Hodges-Lehmann estimation. | All participants who have received at least 1 dose of double-blind study intervention and have data for both timepoints. | Posted | Median | Full Range | Percent Change | Baseline and Week 24 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24 | Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C <70 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage. | All participants who have received at least 1 dose of double-blind study intervention and have baseline data. | Posted | Number | Percentage of Participants | Baseline and Week 24 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24 | Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C <55 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage. | All participants who have received at least 1 dose of double-blind study intervention and have baseline data. | Posted | Number | Percentage of Participants | Baseline and Week 24 |
|
|
Up to 64 weeks.
All-Cause Mortality is reported for all randomized participants. Serious Adverse Events and Other Adverse Events are reported for all participants who received treatment. One participant received enlicitide decanoate at 56 weeks outside of protocol-specified duration of treatment and was followed for AEs up to 64 weeks (per protocol, 8 weeks postdose).
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Enlicitide Decanoate | Participants received 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks. | 1 | 202 | 9 | 202 | 102 | 202 |
| EG001 | Placebo | Participants received enlicitide decanoate-matching placebo orally QD for up to 52 weeks. | 0 | 101 | 4 | 101 | 43 | 101 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Angina pectoris | Cardiac disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Secondary adrenocortical insufficiency | Endocrine disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Haemorrhoids | Gastrointestinal disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Death | General disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Oral infection | Infections and infestations | MedDRA 28.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 28.0 | Systematic Assessment |
| |
| Hand fracture | Injury, poisoning and procedural complications | MedDRA 28.0 | Systematic Assessment |
| |
| Head injury | Injury, poisoning and procedural complications | MedDRA 28.0 | Systematic Assessment |
| |
| Ischaemic stroke | Nervous system disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Presyncope | Nervous system disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Device dislocation | Product Issues | MedDRA 28.0 | Systematic Assessment |
| |
| Haemorrhagic ovarian cyst | Reproductive system and breast disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Hypertensive crisis | Vascular disorders | MedDRA 28.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 28.0 | Systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA 28.0 | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA 28.0 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 28.0 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 28.0 | Systematic Assessment |
| |
| Accidental overdose | Injury, poisoning and procedural complications | MedDRA 28.0 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 28.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 28.0 | Systematic Assessment |
|
Authorship will be determined in line with International Committee of Medical Journal Editors authorship requirements.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme LLC | 1-800-672-6372 | ClinicalTrialsDisclosure@msd.com |
| Feb 5, 2026 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| D006938 | Hyperlipoproteinemia Type II |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D008052 | Lipid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D006951 | Hyperlipoproteinemias |
Not provided
Not provided
| ID | Term |
|---|---|
| C000728674 | MK-0616 |
Not provided
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|